Lv2
178 积分 2024-08-20 加入
Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead
3天前
已完结
Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy
18天前
已完结
Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy
18天前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2个月前
已完结
Multivariate meta‐analysis
3个月前
已完结
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
4个月前
已完结
Benefit with MRD-guided treatment in CLL
4个月前
已完结
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
5个月前
已完结
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
5个月前
已完结
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
5个月前
已完结
皖公网安备34019202002308
